anaxirone has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, H; Fiebig, HH; Henss, H; Klee, M; Peukert, M; Queisser, W; von Bültzingslöwen, F | 1 |
| Bruntsch, U; Dodion, P; Hansen, HH; Hansen, M; Pinedo, HM; Renard, J; Ten Bokkel Huinink, WW; Van Glabbeke, M | 1 |
2 other study(ies) available for anaxirone and Adenocarcinoma
| Article | Year |
|---|---|
Phase II trial of anaxirone in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Triazoles | 1987 |
Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Thrombocytopenia; Triazoles | 1986 |